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Background: There is partially conflicting evidence on the influence of the steroid hormones estrogen (E) and
progesterone (P) on the development of ovarian cancer (OC). The aim of this study was to assess the expression of
the receptor isoforms ER-α/-β and PR-A/-B in OC tissue and to analyze its impact on clinical and pathological
features and patient outcome.
Methods: 155 OC patients were included who had been diagnosed and treated between 1990 and 2002. Patient
characteristics, histology and follow-up data were available. ER-α/-β and PR-A/-B expression were determined by
immunohistochemistry.
Results: OC tissue was positive for ER-α/-β in 31.4% and 60.1% and PR-A/-B in 36.2% and 33.8%, respectively. We
identified significant differences in ER-β expression related to the histological subtype (p=0.041), stage (p=0.002)
and grade (p=0.011) as well as PR-A and tumor stage (p=0.03). Interestingly, median receptor expression for ER-α
and PR-A/-B was significantly higher in G1 vs. G2 OC. Kaplan Meier analysis revealed a good prognosis for ER-α
positive (p=0.039) and PR-B positive (p<0.001) OC. In contrast, ER-β negative OC had a favorable outcome
(p=0.049). Besides tumor grade and stage, Cox-regression analysis showed PR-B to be an independent prognostic
marker for patient survival (p=0.009, 95% CI 0.251-0.823, HR 0.455).
Conclusion: ER-α/-β and PR-A/-B are frequently expressed in OC with a certain variability relating to histological
subtype, grade and stage. Univariate analysis indicated a favorable outcome for ER-α positive and PR-B positive OC,
while multivariate analysis showed PR-B to be the only independent prognostic marker for patient survival. In
conclusion, ER and PR receptors may be useful targets for a more individualized OC therapy.
Keywords: Estrogen receptor alpha (ER-α), Estrogen receptor beta (ER-β), Progesterone receptor A (PR-A),
Progesterone receptor B (PR-B), Ovarian cancer, Survival, PrognosisBackground
There are various hypotheses to explain the etiology of
ovarian cancer (OC), two of them discussing hormonal
influence on OC tumorgenesis [1,2]. Until today, the in-
fluence of hormones on the development or progression
of OC remains under discussion [3,4]. Some hormonal
risk factors for the development of OC like nulliparity* Correspondence: Miriam.Lenhard@med.uni-muenchen.de
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reproduction in any medium, provided the orand infertility have been identified in epidemiologic
studies, while pregnancy and oral contraceptives seem to
protect from the disease [1,5].
The two steroid hormones estrogen and progesterone
act via different hormone receptors. Estrogen (E) and pro-
gesterone (P) bind to a nuclear receptor (R), estrogen in
addition to an intracellular transmembrane receptor,
which is the G-protein-coupled receptor GPR30 [6,7]. In
this study we focus on the nuclear receptors ER and PR.
Different ER and PR isoforms have been described,
ER-α/-β and PR-A/-B, with only slight differences in re-
ceptor composition. The PR-A isoform for instance lacksl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 OC patient characteristics
OC tissue samples
OC patients (n) 155
Age at primary diagnosis 59 (range 21–88)
Median age (a) 10 (6.7)
< 40 (n, %) 23 (15.3)
40–49 (n, %) 61 (40.7)
50–65 (n, %) 56 (37.3)
>65 (n, %)




Tumor grade (%) low grade 27.2
intermediate 36.5
high grade 36.3
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[8,9]. Their differential regulation of gene transcription
might explain their diverse influence on OC progression
and prognosis [10]. Progesterone is generally assumed to
act antagonistically to oestrogen-mediated cell prolifera-
tion [11], though its specific role in OC is unknown. The
classic steroid hormone receptors ER-α and PR-A show
different effects on OC cells in vitro and in vivo than the
recently discovered receptors ER-β and PR-B [12-16].
In contrast to breast cancer or endometrial cancer, where
steroid hormone receptor expression is well characterized
and known to have therapeutic and prognostic relevance
[17,18], there are only few studies with partly contradictory
results on OC and ER or PR expression [19,20].
The present study was therefore designed to further
analyze ER-α/-β and PR-A/-B expression in a large co-
hort of OC patients and to assess its impact on clinical
and pathological features and patient outcome.
Methods
Tissue samples
All tissue samples were gained at surgery in patients who
had been operated for primary OC at our institution be-
tween 1990 and 2002. Staging and grading were per-
formed by an experienced gynecologic pathologist (D.M.)
according to the criteria of the International Federation
of Gynaecologists and Obstetricians (FIGO) and the
World Health Organization (WHO). Patients with ovar-
ian low malignant potential tumors were excluded from
the study. Patient’s clinical data were available from pa-
tient charts, aftercare files and tumor registry database
information. The main outcomes assessed were disease
recurrence and patient survival. For survival analysis,
survival time was defined as the time between the date of
primary ovarian cancer diagnosis and the date of death.
Ethics approval
The study has been approved by the local ethics com-
mittee of the Ludwig-Maximilians University Munich
(approval with the reference number 138/03) and has
been carried out in compliance with the guidelines of
the Helsinki Declaration of 1975. The study partici-
pants gave their written informed consent and samples
and clinical information were anonymized for statis-
tical workup.
Immunohistochemistry
Immunohistochemistry was performed using a combin-
ation of pressure cooker heating and the standard
streptavidin-biotin-peroxidase complex with the use of
the mouse-IgG-Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, CA) [21]. Primary antibodies used
for immunohistochemical staining were anti-ER-α/-β
and anti-PR-A/B.In short, paraffin-fixed tissue sections were dewaxed
with xylol for 15 min, then dehydrated in ascending con-
centrations of alcohol (70-100%). Afterwards, they were
exposed for epitope retrieval for 10 min in a pressure
cooker using sodium citrate buffer (pH 6.0) containing 0.1
M citric acid and 0.1 M sodium citrate in distilled water.
After cooling, slides were washed in PBS twice. Endogen-
ous peroxidase activity was quenched by dipping in 3%
hydrogen peroxide (Merck, Darmstadt, Germany) in
methanol for 20 min. Non-specific binding of the primary
antibodies was blocked by incubating the sections with
“diluted normal serum” (10 ml PBS containing 150 μl
horse serum; Vector Laboratories, CA) for 20 min at room
temperature. Then, slides were incubated with the primary
antibodies at room temperature for 60 min. After washing
with PBS, slides were incubated in diluted biotinylated
anti-serum secondary antibody (10 ml PBS containing
50 μl horse serum, Vector Laboratories, CA) for 30 min
at room temperature. After incubation with the avidin-
biotin-peroxidase complex (diluted in 10 ml PBS,
Vector Laboratories, CA) for 30 min and repeated PBS
washing, visualization was conducted using substrate
and chromagen 3,3’-diaminobenzidine (DAB, Dako,
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counterstained with Mayer’s acidic hematoxylin and
dehydrated in ascending concentrations of alcohol
(50–98%). After xylol treatment, slides were covered.
Human breast cancer and colon tissue served as posi-
tive controls, human ileum as negative. Positive staining
appeared in brownish colour, negative as well as un-
stained tissue blue.
Immunohistochemical analysis
Slides were evaluated and digitalized with a Zeiss photomi-
croscope (Axiophot, Axiocam, Zeiss, Jena, Germany).
Immunohistochemical staining was assessed using a semi-
quantitative score according to Remmele and Steger [22],
comprising optical staining intensity (graded as 0 = no,
1 = weak, 2 = moderate, and 3 = strong staining) and the
percentage of positively stained cells (0 = no, 1 = <10%, 2 =
11–50%, 3 = 51–80% and 4 = >81% cells). The final score is
the sum of intensity and percentage scores. According to
previously published data, we scored the tumor tissue as
positive if more than 10% of cells were scored with an
immunoreactive score (IRS) higher than 2 [17,22]. The
slides were reviewed in a blinded fashion by two independ-
ent observers, including a gynecological pathologist (D.M.).
Statistical analysis
Statistical analysis was performed using SPSS 18.0 (PASW
Statistic, SPSS Inc., IBM, Chicago, IL). Differences in OCFigure 1 Representative slides of immunohistochemical staining for E
and 25x), PR-A (C, magnification 10x and 25x) and PR-B (D, magnifica
assessed according to the immunoreactive score (IRS) by Remmele and Stereceptor expression among three or more groups were
tested using the non-parametric Kruskal-Wallis rank-sum
test and for pairwise comparisons using the non-
parametric Mann–Whitney-U rank-sum test. Correlation
analysis was performed using the Spearman correl-
ation coefficient. For the comparison of survival times,
Kaplan-Meier curves were drawn. The chi-square statis-
tic of the log-rank test was calculated to test differences
between survival curves for significance. Multivariate
analysis for prognostic value was performed using the
Cox-regression model. P values below 0.05 were consid-
ered statistically significant.Results
Patient characteristics
Paraffin embedded tissue of 155 OC patients was avail-
able. Median age at primary diagnosis was 59 years
(range 21–88). Most patients presented with progressed
disease at primary diagnosis [FIGO I: n=35 (22.6%),
FIGO II: n=9 (5.8%), FIGO III: n=109 (70.3%), FIGO IV:
n=2 (1.3%)]. Patient characteristics are shown detailed in
Table 1. Median follow-up time was 12.2 years (95% CI:
9.7-14.6). With 28 documented relapses and 104 deaths,
median relapse free survival was 3.7 years (95% CI: 1.9-
5.6) and median overall survival 3.4 years (95% CI: 2.2-
4.7). Patients with ovarian low malignant potential
tumor were excluded from this study.R-α (A, magnification 10x and 25x), ER-β (B, magnification 10x
tion 10x and 25x) in serous OC. Immunohistochemical staining was
ger [22]. No receptor immunoreactivity was detected in tumor stroma.
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Figure 2 (See legend on next page.)
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Figure 2 Median receptor expression for the histological subtype (a), grade (b) and stage (c). a: Receptor expression and histological
subtype. Significant differences were observed for * ER-β: serous vs. endometrioid (p=0.024), # PR-A: serous vs. mucinous (p=0.049)
[Mann–Whitney U] and ER-β (all subtypes): p=0.041 [Kryskal Wallis]. b: Receptor expression and tumor grade. Significant differences were
observed for * ER-α: G1 vs. G2 (p=0.028), # ER-β: G1 vs. G2 (p=0.002), ° PR-A: G1 vs. G2 (p=0.048), ^ PR-B: G1 vs. G2 (p=0.038) [Mann–Whitney U]
and ER-β (G1-G3): p=0.011 [Kruskal Wallis]. c: Receptor expression and tumor stage. Significant differences were observed for * ER-β: FIGO I vs. II
(p=0.005), # ER-β: FIGO I vs. III (p=0.001), ° PR-A: FIGO I vs. II (p=0.019), ^ PR-A: FIGO II vs. III (p=0.017), x PR-A: FIGO II vs. IV (p=0.036), “ PR-B: FIGO
II vs. III (p=0.017), ~ PR-B: FIGO II vs. IV (p=0.034) [Mann–Whitney U] and ER-β (FIGO I-IV): p=0.011 and PR-A (FIGO I-IV): p=0.030 [Kruskal Wallis].
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OC tissue was positive for ER-α/-β in 31.4% and
60.1% and PR-A/-B in 36.2% and 33.8%, respectively
(Table 1 and Figure 1A-D). Highest mean IRS accord-
ing to the histological subtype was noted for ER-β
(mean IRS 3.54±0.259), followed by PR-B (mean IRS
3.44±0.280), PR-A (mean IRS 2.15±0.249) and ER-α
(mean IRS 1.90±0.214).
The only statistically significant difference in receptor
expression of all subtypes was observed for ER-β
(p=0.041) (Figure 2a). Pairwise comparison of histo-
logical subtypes showed a significant difference for ER-β
and the serous vs. endometrioid (p=0.024) and PR-A and
the serous vs. mucinous (p=0.049) subtype (Figure 2a).
Significant differences in steroid receptor expression
and all tumor grades were observed for ER-β only
(p=0.011) (Figure 2b). Interestingly, pairwise comparison
showed a significantly higher median receptor expres-
sion in G1 vs. G2 for ER-α and PR-A/-B, but inversely
low receptor expression in G1 vs. G2 for ER-β tumors
[ER-α: G1 vs. G2 (p=0.028), ER-β: G1 vs. G2 (p=0.002),
PR-A: G1 vs. G2 (p=0.048), PR-B: G1 vs. G2 (p=0.038)]
(Figure 2b).
Comparing all median tumor stages, a significantly
different receptor expression was noticed for ER-β
(p=0.011) and PR-A (p=0.030). Moreover, pairwiseTable 2 Correlation between ER-α, ER-β, PR-A, PR-B, LH-R and
Correlations ER-α ER-β
ER-α Correlation Coefficient - 0.058
Sig. (2-tailed) - NS
N - 153
ER-β Correlation Coefficient 0.058 -
Sig. (2-tailed) NS -
N 153 -
PR-A Correlation Coefficient 0.236** 0.234**
Sig. (2-tailed) 0.003 0.004
N 152 150
PR-B Correlation Coefficient 0.237** 0.133
Sig. (2-tailed) 0.003 NS
N 154 152
** Correlation is significant at the 0.01 level (2-tailed) * Correlation is significant at t
NS=not significant.analysis showed statistically significant differences for
ER-β in FIGO I vs. II (p=0.005) and I vs. III (p=0.001),
for PR-A in FIGO I vs. II (p=0.019), II vs. III (p=0.017)
and II vs. IV (p=0.036) and PR-B in FIGO II vs. III
(p=0.017) and II vs. IV (p=0.034) (Figure 2c).
Receptor correlations
We found various positive but no significant negative
correlations between ER-α, ER-β, PR-A and PR-B
expressions (Table 2). PR-B for instance, which we found
to be of prognostic value in this study (see results
below), correlates significantly with ER-α (correlation co-
efficient 0.237, p=0.003) and PR-A (correlation coeffi-
cient 0.622, p<0.001) (Table 2).
Prognostic value
Statistical analysis was performed to test for a prognostic
value of ER-R or PR-R expression. Univariate Kaplan
Meier analysis revealed a good prognosis for ER-α posi-
tive (p=0.039) (Figure 3a) and PR-B positive OC
(p<0.001) (Figure 3d) OC. Moreover, ER-β negative OC
had a favorable outcome (p=0.049) (Figure 3b). A similar
trend was observed for the relapse free interval, though
not reaching statistical significance (p>0.05). Besides
tumor grade and stage, multivariate Cox-regression ana-
lysis showed PR-B to be the only independent prognosticFSH-R
PR-A PR-B LH-R FSH-R
0.236** 0.237** 0.045 0.104
0.003 0.003 NS NS
152 154 154 151
0.234** 0.133 0.032 −0.026
0.004 NS NS NS
150 152 151 148
- 0.622** −0.164* 0.069
- <0.001 0.045 NS
- 152 150 147
0.622** - −0.031 −0.060
<0.001 - NS NS
152 - 152 149




































































Figure 3 Kaplan Meier survival analysis for ER-α (a), ER-β (b), PR-A (c) and PR-B (d) receptor expression in OC patients. a: ER-α positive
vs. negative OC. b: ER-β positive vs. negative OC. c: PR-A positive vs. negative OC. d: PR-B positive vs. negative OC.
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0.823, p=0.009) (Table 3).
Discussion
There are several studies describing ER and PR expres-
sion in breast, endometrial or prostate cancer [17,18,23].
In this study we assessed ER-α/-β and PR-A/-B tissue
expression in OC by immunohistochemistry. OC tissue
was positive for ER-α/-β in 31.4% and 60.1% and PR-A/-B
in 36.2% and 33.8%, respectively. In literature there arecomparable results, though a wide range of steroid re-
ceptor expression in OC is reported, namely 32–77% for
ER and 26-43% for PR [19,24,25]. The great variability
described for steroid hormone receptor expression in OC
is probably attributable to different analytical methods,
e.g. biochemical assays like the Dextran-coated charcoal
method in former times and immunohistochemistry or re-
verse transcription–polymerase chain reaction (RT–PCR)
today [20,24,26,27]. Even within one analytical method,
results differ with regard to diverse cut-offs or scoring
Table 3 COX regression analysis for patient survival





Grade 1 vs. Grade 2 0.393 0.194 0.798 0.010
Grade 1 vs. Grade 3 0.727 0.452 1.169 0.188
Stage 0.001
FIGO I vs. FIGO II 0.113 0.022 0.569 0.008
FIGO I vs. FIGO III 0.333 0.057 1.929 0.220
FIGO I vs. FIGO IV 0.485 0.110 2.136 0.338
Age <50a vs. >50a 1.026 0.555 1.895 0.935
ER-α positive vs. ER-α negative 0.660 0.397 1.098 0.110
ER-β positive vs. ER-β negative 1.108 0.687 1.788 0.673
PR-A positive vs. PR-A negative 1.436 0.825 2.500 0.201
PR-B positive vs. PR-B negative 0.455 0.251 0.823 0.009
HR=hazard ratio, CI=confidence interval.
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sion studies for OC have a limited tumor selection by
restricting patient inclusion criteria to a certain histo-
logical subtype, grade or tumor stage [25,29]. But most
important for the interpretation of ER and PR results in
OC is the comparison of the identical steroid hormone
receptor isoforms. As shown here in our study, tissue ex-
pression, receptor correlations and survival results for
ER-α vs. ER-β or PR-A vs. PR-B differ in a wide range.
Another limitation are the commercially available anti-
bodies, which are suspected to have a variable affinity to
steroid hormone receptors, potentially resulting in
underestimation of receptor expression [30].
In vivo and in vitro studies reveal varying effects of
estrogen and progesterone on OC cells. OC cell growth
is mainly induced through ER-α, because at in vitro ana-
lysis only 17-beta-estradiol induced cell growth, a specific
ER-α but not ER-β agonist [12]. Altogether, there is in-
creasing evidence that ER-α is a tumor promoter acting
on OC cell growth and proliferation, whereas ER-β has
been described to have proapoptotic and antiproliferative
effects [13,14]. Simpson et al. described PR-A to function
as a transcriptional inhibitor of ER [15]. Kumar et al.
found PR-B to be involved in cell differentiation [16].
Our clinical data confirm that there are interactions
between ER and PR receptors as we observed several
significant receptor correlations between ER-α, ER-β,
PR-A and PR-B. Most importantly, PR-B, which we
found to be of prognostic value in this study, appears to
correlate significantly positively with ER-α and PR-A.
This observation had previously also been made by
others [31]. There was no correlation for PR-B and
tumor stage, grade or histological subtype in this study.
This finding is in accordance with a study of 322 OCtumor samples in which PR expression was not asso-
ciated with tumor grade or clinical stage [24]. In con-
trast, others found a correlation with early clinical stage,
less presence of ascites and better tumor differentiation
[32]. Again, the comparison of study results is limited
since there was no further differentiation of the ER and
PR receptor isoforms.
Prognostic markers which could support a more indi-
vidualized anti-OC therapy are scarce. Especially the
prognostic roles of ER and PR have been discussed con-
troversially. In this study, PR-B has been identified as an
independent prognostic marker for OC patient survival
beside tumor grade and stage. Moreover, ER-α positive
and PR-B positive OC had a favorable outcome. In con-
trast, ER-β negative OC had a better survival. Our data
are in accordance with studies by others who also found
higher PR status [29], increased ER or combined ER/PR
positive tumors to be associated with a favourable pa-
tient outcome [20,24,26,27]. Akhahira et al. examined
the two isoforms PR-A and PR-B and ER-α by immuno-
histochemistry (107 cases) and reverse transcription-
polymerase chain reaction (RT-PCR; 16 cases) [31]. They
observed PR-B to be the only analyzed hormone receptor
with prognostic relevance on multivariate analysis [31].
This finding is in agreement with our data presented
here. Nonetheless, there are also studies showing no
impact of ER or PR expression on patient survival [28,33].
In this study, a negative correlation of PR-A and LH-R
expression was noted. Interestingly, our previously pub-
lished data showed a prognostic value of LH-R in this
patient group [34]. Since we only observed a prognostic
value of PR-B but not of PR-A expression, this might
also be attributable to PR-A and LH-R interactions.
Clinical study results using anti-estrogen or aromatase
inhibitor therapy were often disappointing. Nearly all clin-
ical studies included patients with all OC subtypes and
histological grades or patients who were extensively pre-
treated with chemotherapy or had bulky disease [35-37].
Reported response rates to tamoxifen range between 0
and 56% [35,38,39]. In a recently published review on
tamoxifen studies in OC, tamoxifen achieved objective
overall response rates of 10% and stable disease rates of
32% [37]. Significantly different response rates to tam-
oxifen have been observed with regard to histological
subtypes [36]. Altogether, it seems that study results
concerning anti-hormone therapy should be stratified
with regard to ER-α, ER-β, PR-A and RP-B expression
since receptor isoforms seem to have varying functions
in vivo and in vitro and therefore have different rele-
vance for patient survival.
Conclusions
To our knowledge, this study is the only work assessing
the expression of the four isoforms ER-alpha, ER-beta,
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series of OC patients. ER-α/-β and PR-A/-B are fre-
quently expressed in OC with a certain variability relat-
ing to histological subtype, grade and stage. Univariate
analysis indicated a favorable outcome for ER-α positive
and PR-B positive OC, while multivariate analysis
showed PR-B to be the only independent prognostic
marker for patient survival. The more specified analy-
sis of steroid receptor expression, e.g. in combination
with other newly identified prognostic markers like the
LH/HCG receptor [34], could assist in choosing a more
individualized and hopefully more effective OC therapy
for certain patients.
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